SCHEMBL1147192

SCHEMBL1147192

COc1ccc2ncnc(OC[C@H]3CC[C@H](C(=O)Nc4ccc5c(c4)OCCO5)CC3)c2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.54
ALDH1A1 P00352 4/20 0.52
MAPT P10636 4/20 0.52
HTT P42858 1/20 0.52
CLK1 P49759 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
SMN1; SMN2 Q16637 4/20 0.50
MTNR1B P49286 2/20 0.49
MTNR1A P48039 1/20 0.49
KDM4E B2RXH2 4/20 0.48
L3MBTL1 Q9Y468 2/20 0.46
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
MAPK1 P28482 2/20 0.46
NPC1 O15118 2/20 0.46
TP53 P04637 1/20 0.46
PKM P14618 1/20 0.46
NFKB1 P19838 1/20 0.46
RAB9A P51151 1/20 0.46
NFKB2 Q00653 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3247108 0.88 MAPT (0.51) KCNH2ALDH1A1MAPTHTTCLK1
SCHEMBL1147533 0.88 KCNH2 (0.60) KCNH2ALDH1A1MAPTHTTCLK1
SCHEMBL3253530 0.81 KCNH2 (0.52) KCNH2ALDH1A1MAPTHTTCLK1
SCHEMBL3126601 0.79 KCNH2 (0.67) KCNH2
SCHEMBL1147911 0.79 TRPV1 (0.46) KCNH2ALDH1A1HTTSMN1; SMN2MTNR1B
SCHEMBL3251040 0.79 MTNR1B (0.53) ALDH1A1NPSR1MTNR1BMTNR1AKDM4E
SCHEMBL3251044 0.79 MTNR1B (0.53) ALDH1A1NPSR1MTNR1BMTNR1AKDM4E
SCHEMBL1147940 0.77 MAPT (0.51) KCNH2ALDH1A1MAPTSMN1; SMN2KDM4E
SCHEMBL1147941 0.77 MAPT (0.51) KCNH2ALDH1A1MAPTSMN1; SMN2KDM4E
SCHEMBL3244126 0.77 KCNH2 (0.49) KCNH2ALDH1A1MAPTHTTCLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250057962-A1 PROCESSABLE COMPOSITIONS AND USE FOR THE SAME RIPPLE THERAPEUTICS CORPORATION (CA) 2025-02-20 US claimed
EP-4426712-A1 PROCESSABLE COMPOSITIONS AND USE FOR THE SAME Ripple Therapeutics Corporation (CA) 2024-09-11 EP claimed
WO-2023079362-A1 PROCESSABLE COMPOSITIONS AND USE FOR THE SAME RIPPLE THERAPEUTICS CORPORATION (CA) 2023-05-11 WO claimed
US-20190038622-A1 NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES WAYNE STATE UNIVERSITY 2019-02-07 US claimed
US-20120196825-A1 COMPOSITIONS AND METHODS FOR MODULATING THE IMMUNE SYSTEM SUPPORTIVE THERAPEUTICS AG (CH) 2012-08-02 US claimed
US-20090156546-A1 Compositions and methods for modulating the immune system SUPPORTIVE THERAPEUTICS AG (CH) 2009-06-18 US claimed
EP-2026810-A2 COMPOSITIONS AND METHODS FOR MODULATING THE IMMUNE SYSTEM Prendergast, Patrick T. (AU) 2009-02-25 EP claimed
US-20080027129-A1 Administration of 3H-1, 2-dithiole-3-thione, anethole dithiolethione, sulforaphane, phenethyl isothiocyanate, 6-(methylsulfinyl)hexyl isothiocyanate and allyl isothiocyanate for the treatment of canities L'OREAL (FR) 2008-01-31 US claimed
EP-1872769-A1 Use of 3h-1,2-dithiole-3-thione, anethole dithiolethione, sulforaphane, phenethyl isothiocyanate, 6-methyl-sulphinyl)hexyl isothiocyanate and allyl isothiocyanate for treating whitening of the hair L'OREAL (FR) 2008-01-02 EP claimed
EP-1858875-A2 ANETHOLE DITHIOLETHIONE AND OTHER DITHIOLETHIONES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH DYSFUNCTION OF MONOAMINE NEUROTRANSMISSION Solvay Pharmaceuticals B.V. (NL) 2007-11-28 EP claimed
WO-2007131973-A2 COMPOSITIONS AND METHODS FOR MODULATING THE IMMUNE SYSTEM PRENDERGAST PATRICK T (AU) 2007-11-22 WO claimed
US-20060194971-A1 Anethole dithiolethione and other dithiolethiones for the treatment of conditions associated with dysfunction of monoamine neruotransmission SOLVAY PHARMACEUTICALS B.V. (NL) 2006-08-31 US claimed
WO-2006089861-A2 ANETHOLE DITHIOLETHIONE AND OTHER DITHIOLETHIONES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH DYSFUNCTION OF MONOAMINE NEUROTRANSMISSION SOLVAY PHARMACEUTICALS B.V. (NL) 2006-08-31 WO claimed
US-7012148-B2 Compositions and methods for thionation during chemical synthesis reactions TRUSTEES OF DARTMOUTH COLLEGE (US) 2006-03-14 US claimed
US-20030176714-A1 Compositions and methods for thionation during chemical synthesis reactions NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-09-18 US claimed
WO-2002026909-A1 COMPOSITIONS AND METHODS FOR THIONATION DURING CHEMICAL SYNTHESIS REACTIONS TRUSTEES OF DARTMOUTH COLLEGE (US) 2002-04-04 WO claimed
US-20250057962-A1 PROCESSABLE COMPOSITIONS AND USE FOR THE SAME RIPPLE THERAPEUTICS CORPORATION (CA) 2025-02-20 US disclosed
EP-4426712-A1 PROCESSABLE COMPOSITIONS AND USE FOR THE SAME Ripple Therapeutics Corporation (CA) 2024-09-11 EP disclosed
WO-2002026909-A1 COMPOSITIONS AND METHODS FOR THIONATION DURING CHEMICAL SYNTHESIS REACTIONS TRUSTEES OF DARTMOUTH COLLEGE (US) 2002-04-04 WO disclosed
WO-2000056299-A2 THE USE OF AMIFOSTINE FOR THE PROTECTION AGAINST TUMOR METASTASIS FORMATION ARCH DEVELOPMENT CORPORATION (US) 2000-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250057962-A1 PROCESSABLE COMPOSITIONS AND USE FOR THE SAME CCND2, CCND1, C9 KCNH2 2116/4885ALDH1A1 2326/4885MAPT 583/4885
US-20080027129-A1 Administration of 3H-1, 2-dithiole-3-thione, anethole dithiolethione, sulforaphane, phenethyl isothiocyanate, 6-(methylsulfinyl)hexyl isothiocyanate and allyl isothiocyanate for the treatment of canities TST, CTH, NOTUM KCNH2 2532/4885ALDH1A1 603/4885MAPT 2487/4885
US-20060194971-A1 Anethole dithiolethione and other dithiolethiones for the treatment of conditions associated with dysfunction of monoamine neruotransmission MAOB, MAOA, DAO KCNH2 3287/4885ALDH1A1 263/4885MAPT 2908/4885
US-20030176714-A1 Compositions and methods for thionation during chemical synthesis reactions TST, TPMT, MTAP KCNH2 3006/4885ALDH1A1 2028/4885MAPT 1401/4885
US-20190038622-A1 NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES SMN1; SMN2, PARK7, SNCA KCNH2 434/4885ALDH1A1 1481/4885MAPT 409/4885
US-20090156546-A1 Compositions and methods for modulating the immune system MRE11, XPA, MPL KCNH2 3331/4885ALDH1A1 3955/4885MAPT 4639/4885
US-20120196825-A1 COMPOSITIONS AND METHODS FOR MODULATING THE IMMUNE SYSTEM MRE11, XPA, MPL KCNH2 3331/4885ALDH1A1 3955/4885MAPT 4639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.